[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100455250":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":33,"centralContacts":37,"locations":47,"responsibleParty":74,"collaborators":10,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":10,"enrollmentInfo":87,"targetDuration":10,"studyType":90,"phases":10,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":101,"whyStopped":10,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Lille Catholic University","OTHER",[8,14],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with Hidradenitis suppurativa",null,[12,13],"Biological: Blood tests","Procedure: exeresis",{"label":15,"type":10,"description":10,"interventionNames":16},"Controls (coming for abdominoplasty)",[17],"Procedure: abdominoplasty",[19,24,29],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"BIOLOGICAL","Blood tests","For patients, it will be performed:\n\n* a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,\n* A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study.",[9],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"PROCEDURE","exeresis","For patients, it will be performed:\n\n\\- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue.",[9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"abdominoplasty","For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:\n\n* four in the center,\n* two in the margin",[15],[34],{"name":35,"affiliation":5,"role":36},"Marie LAMIAUX","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Amélie LANSIAUX, Md, PhD","CONTACT","+33320225269","lansiaux.amelie@ghicl.net",{"name":44,"role":40,"phone":45,"phoneExt":10,"email":46},"Anne-Sophie BLAIN, CRA","+33320225732","blain.anne-sophie@ghicl.net",[48,62],{"facility":49,"status":10,"city":50,"state":10,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Hôpital Saint Vincent-de-Paul, Service de Dermatologie-Vénéréologie","Lille","59020","France","FR",{"type":55,"coordinates":56},"Point",[57,58],3.05512,50.63391,{"lat":58,"lon":57},[61],{"name":35,"role":40,"phone":10,"phoneExt":10,"email":10},{"facility":63,"status":10,"city":64,"state":10,"zip":65,"country":52,"countryCode":53,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Hôpital Saint Philibert - Service de Chirurgie Viscérale","Lomme","59462",{"type":55,"coordinates":67},[68,69],2.98715,50.64358,{"lat":69,"lon":68},[72],{"name":73,"role":40,"phone":10,"phoneExt":10,"email":10},"André DABROWSKI",{"type":75,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100455250","study-of-the-immunomodulation-in-the-hidradenitis-suppurativa-and-evaluation-of-a-new-therapeutic-strategy-100455250",false,"NCT05208099","Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy","Study of the Immunomodulation of the Immune Response in Hidradenitis Suppurativa and in Vitro and ex Vivo Evaluation of a New Therapeutic Strategy (IMOHS)","IMOHS","Inclusion criteria for HS patients :\n\n* Adult patients (≥18 years)\n* Carrier of moderate to severe (Hurley grade ≥2) hidradenitis suppurativa of classical or gluteal phenotype\n* Having an indication for surgical treatment (indication for excision)\n* Not receiving immunomodulatory treatments (corticotherapy, biotherapy, apremilast, retinoids) or immunosuppressive treatments (methotrexate, ciclosporin) in the 6 months before inclusion, excluding antibiotics\n* Agreement to participate\n* Affiliated to social security\n\nInclusion criteria for control receiving abdominoplasty :\n\n* Adult patients (≥18 years)\n* With no history of hidradenitis suppurativa or lesions suggestive of hidradenitis suppurativa (recurrent fold abscesses, recurrent fold suppuration, repeated draining in fold areas)\n* With an indication for abdominoplasty surgery\n* Not receiving immunomodulatory treatments (corticotherapy, biotherapy, apremilast, retinoids) or immunosuppressive treatments (methotrexate, ciclosporin) in the 6 months preceding inclusion, excluding antibiotics\n* Agreement to participate\n* Affiliated to social security\n\nCriteria for non-inclusion of patients with HS :\n\n* Immunosuppression, autoimmune disease(s), cancerous disease, or acute or chronic infectious disease\n* Difficulty understanding or reading French\n* Patients already included in a therapeutic interventional trial\n* Patients under guardianship or curatorship\n* Pregnant or breast feeding women\n* Syndromic hidradenitis suppurativa, hidradenitis suppurativa of follicular phenotype\n\nCriteria for non-inclusion of controls receiving abdominoplasty :\n\n* Immunosuppression, autoimmune disease(s), cancerous disease, or acute or chronic infectious disease\n* Difficulty understanding or reading french\n* Patients already included in a therapeutic interventional trial\n* Patients under guardianship or curatorship\n* Pregnant or breastfeeding women",true,"ALL","18 Years",{"count":88,"type":89},20,"ESTIMATED","OBSERVATIONAL","Hidradenitis suppurativa (HS), also known as Verneuil's disease, is a chronic inflammatory dermatosis of the hair follicule located mainly in the skin folds (axillae, inguinal, submammary, etc.).\n\nCurrently, treatments are mainly limited to the use of broad-spectrum antibiotics in order to control outbreaks of hidradenitis suppurativa. Surgical treatment is the only curative treatment, but requires disfiguring removals with major scarring consequences.\n\nPathophysiologically, HS appears to be a primary abnormality of the pilosebaceous-apocrine unit, causing follicular occlusion, followed by the development of perifollicular cysts with commensal bacterial overgrowth, and finally rupture into the dermis causing an exaggerated inflammatory response. At present, few studies have examined the role of the regulatory immune system and its involvement in this disease.\n\nWe are also interested in analyzing the impact of new therapeutic strategies on hidradenitis suppurativa, and more particularly the impact of photodynamic therapy (PDT) which is a technique that has been used for a long time in dermatology, notably for the treatment of precancerous and cancerous lesions.\n\nThis technique has shown interesting results on inflammatory dermatoses such as acne.\n\nThis research consists in studying the immunomodulation of the immune response in HS and in evaluating a new therapeutic strategy based on PDT alone or in combination with antimicrobial peptides (PAMs).",[93],"Hidradenitis Suppurativa",[95,96,97,98,99,100],"Hidradenitis suppurativa","inflammatory nodules","abscesses","fistulas","scars","surgery","NOT_YET_RECRUITING","2023-10-30",{"date":104,"type":105},"2023-10-31","ACTUAL",{"date":107,"type":89},"2024-01-01",{"date":109,"type":89},"2026-06-30",{"name":5,"class":6},2]